ArticleNature2023
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers.
0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed
39.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
201 citing papers in PubMed, 239 citations in OpenAlex.
- Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progression.Cancer biology & therapy · 2026Article
- Article
- Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026Review
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- TERT drives liver tumorigenesis beyond telomere elongation.Life science alliance · 2026Article
- L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial.Nature cancer · 2026Article
- The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.Experimental hematology & oncology · 2026Review
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- A proximity ligation screen identifies SNAT2 as a novel target of the MARCH1 E3 ubiquitin ligase.Biology open · 2026Article
- Article
- METTL7A Downregulation Drives SLC1A5-Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Loss of TET2 sulfhydration results in destabilization of TET2 and down-regulation of the immune response in melanoma.Acta pharmaceutica Sinica. B · 2026Article
- Review
- Metabolic rewiring of the dendritic cell-T cell axis: tumour-derived barriers and therapeutic opportunities.Experimental & molecular medicine · 2026Review
- Enzymatic Hydrolysates fromMarine drugs · 2026Article
- Fibroblast-specific ablation of MHC-I antigen presentation via the IGF2 axis cripples CD8Science advances · 2026Article
- Review
- TGF-β coordinates alanine synthesis and import for myofibroblast differentiation in pulmonary fibrosis.JCI insight · 2026Article
141 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Chuansheng GuoDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Zhiyuan YouDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Hao ShiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-2796-629X
Yu SunDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Xingrong DuDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Gustavo PalaciosDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cliff GuyDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sujing YuanDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Nicole M ChapmanDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Seon Ah LimDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-6560-4874
Xiang SunDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jordy SaraviaDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-2691-501X
Sherri RankinDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Yogesh DhunganaDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Hongbo ChiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA. hongbo.chi@stjude.org.ORCID 0000-0002-9997-2496
St. Jude Children's Research Hospital · US
Funding
Integrating systems immunology with immunometabolism and cancer immunityR35CA253188 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2021 to 2026
$6.0MRegulation of TH17 plasticity and stemness by mTORC1R01AI131703 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$4.1MTranscriptional and metabolic heterogeneity in T cell differentiationR01AI140761 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$3.9MMetabolic checkpoint in dendritic cell subsets and adaptive immunityR37AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.6MBidirectional signaling in T cell differentiationR01AI150241 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.3MNutrient sensing and lysosomal signaling in regulatory T cells and immune toleranceR01AI150514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2019 to 2023
$2.2MMetabolic checkpoint in TH17 cell differentiationR01AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2014 to 2018
$2.2MNCI NIH HHS R35 CA253188NIAID NIH HHS R01 AI105887NIAID NIH HHS R01 AI131703NIAID NIH HHS R01 AI140761NIAID NIH HHS R01 AI150241NIAID NIH HHS R01 AI150514NIAID NIH HHS R37 AI105887
Abstract
Cancer cells evade T cell-mediated killing through tumour-immune interactions whose mechanisms are not well understood
Indexed as
Amino Acid Transport System ADendritic CellsGlutamineNeoplasmsSignal TransductionBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCD8-Positive T-LymphocytesProto-Oncogene ProteinsTumor Suppressor ProteinsAmino Acid Transport System ABasic Helix-Loop-Helix Leucine Zipper Transcription FactorsGlutamineProto-Oncogene ProteinsTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.